Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Posts 20-Percent Revenue Increase in Q4

NEW YORK, March 8 (GenomeWeb News) - Stratagene said today that its revenues for the fourth quarter grew 20 percent to $22.8 million, compared with $18.9 million in the fourth quarter of 2003. The company said that $5.6 million was related to Stratagene's acquisition of Hycor in June 2004.


The La Jolla, Calif.-based company spent approximately $2.7 million on research and development in the fourth quarter of 2004, a slight increase from the approximately $2.3 million it spent on R&D in Q4 2003.


Stratagene also said net income surged to $1.9 million, or $.08 per diluted share, from $237,000, or $.02 per diluted share in the year-ago period.


As of Dec. 31, 2004, Strategene had cash, cash equivalents, and marketable securities totaling $5.7 million, and total assets of $80.2 million.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.